Biopharma efforts to revitalize reform of the US drug rebate system will mobilize again after the November presidential election, policy experts suggested during a panel session on drug pricing at the Biotechnology Innovation Organization’s virtual international convention.
Although the COVID-19 pandemic has sidelined major initiatives in the near term, concerns with high drug prices have not gone away and panelists suggested that various
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?